Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections

J Thorac Cardiovasc Surg. 2023 Oct;166(4):1222-1231.e1. doi: 10.1016/j.jtcvs.2023.01.019. Epub 2023 Jan 25.

Abstract

Objective: This study aimed to evaluate the long-term prognosis of patients with peripheral small ground-glass opacity-dominant lung cancer after sublobar resection. We have already reported the 5-year safety and efficacy of sublobar resection and report the long-term outcomes after a 10-year follow-up period.

Methods: Between May 2009 and April 2011, 333 patients with radiologically noninvasive peripheral lung cancer were enrolled from 51 institutions (median age, 62 years at registration) and followed up until May 6, 2021. Of these patients, sublobar resections with wedge resection as the first choice were performed in 314 patients (258 wedge resections and 56 segmentectomies), conversion lobectomies were performed in 11 patients, and 8 patients were ineligible.

Results: The 10-year relapse-free survival and overall survival for the 314 patients with sublobar resections were 98.6% (95% confidence interval, 96.2-99.5) and 98.5% (95% confidence interval, 96.1-99.4), respectively. There was 1 local recurrence at the resection margin. Among the patients, second cancers were observed in 43 patients (13.4%; 95% confidence interval, 9.8-17.6), of which 18 were second lung cancers (5.8%; 95% confidence interval, 3.5-8.9).

Conclusions: Peripheral ground-glass opacity-dominant lung cancer is cured by sublobar resection, with wedge resection as the first choice, and the indications for other treatment options should be further investigated. The incidence of second cancer is similar to that in the general Japanese population.

Keywords: ground-glass opacity; long-term prognosis; lung cancer; second cancer; sublobar resection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lung Neoplasms* / diagnostic imaging
  • Lung Neoplasms* / surgery
  • Margins of Excision
  • Middle Aged
  • Neoplasms, Second Primary*